SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Keryx Biopharmaceuticals, Inc (KERX)

KERX RSS Feed
Add KERX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/12/2017 1:53:37 PM - Followers: 139 - Board type: Free - Posts Today: 0

 

 

 

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both multiple myeloma and refractory advanced colorectal cancer, and in Phase 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing ZerenexTM (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx also actively engages in business development activities that include seeking strategic relationships for its product candidates, as well as evaluating compounds and companies for in-licensing or acquisition.

Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."





Corporate Headquarters

 

Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY 10022
Phone: 1-212-531-5965
Fax: 1-212-531-5961
Contact Email
Investor Relations IR@keryx.com
Business Development BusDev@keryx.com
Clinical Trials ClinicalTrials@keryx.com
Employment Opportunities

Company Website
jobs@keryx.com

http://www.keryx.com/



 

Product candidate Target indication Development status
     
ZerenexTM (ferric citrate) Hyperphosphatemia in patients with end-stage renal disease U.S. Phase 3 program ongoing under SPA; 
Japan Phase 3 program ongoing by sublicensee (JT and Torii)

 

Recent News:

http://ih.advfn.com/p.php?pid=news&symbol=N%5EKERX

http://www.otcmarkets.com/stock/KERX/news  

http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-news&nyo=0

Charts:

Gallery views:

http://stockcharts.com/freecharts/gallery.html?kerx


 

                KERX - Daily Candlesticks  


Analyst's estimates and ratings: 
http://investing.money.msn.com/investments/analyst-ratings/?symbol=kerx

http://www.marketwatch.com/investing/stock/KERX/analystestimates?subview=snapshot&pg=analyst

 

The most recent Quarterly (10-Q)
 
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8450533

Do your own DD and trade smart.


 
 
  
SureTrader
Interactive Brokers Advertisement
KERX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KERX News: Current Report Filing (8-k) 12/13/2017 04:31:53 PM
KERX News: Confidential Treatment Order (ct Order) 12/04/2017 05:27:31 PM
KERX News: Confidential Treatment Order (ct Order) 12/04/2017 05:20:34 PM
KERX News: Consolidated Research: 2018 Summary Expectations for Schlumberger N.V, W.W. Grainger, Best Buy Co., Acadia Realty Trust, Kery... 11/29/2017 08:30:00 AM
KERX News: Amended Statement of Ownership (sc 13g/a) 11/20/2017 04:13:03 PM
PostSubject
#3135   Seth you old dog you been playing this smile86 12/12/17 01:53:37 PM
#3134   If there was GOOD new this would be smile86 12/12/17 09:37:46 AM
#3133   Don't look like FDA gave it OK. Stock smile86 12/07/17 12:06:56 PM
#3132   KERX is nothing but a disappointment in my portfolio.. lakingsphan0427 12/05/17 06:56:15 PM
#3131   According to the Keryx "News" there is a Swiss-Alan 12/05/17 12:31:26 PM
#3130   Been accumulating shares under 5$, this is money! harry crumb 11/29/17 07:36:16 PM
#3129   Ha, that's what you meant. Thanks, makes sense. H2R 11/15/17 05:48:31 PM
#3128   Charting! Do u know how to read a harry crumb 11/15/17 05:40:46 PM
#3127   I didn't biopa maybe they had a good lakingsphan0427 11/15/17 11:18:04 AM
#3126   Did anyone hear the presentation today? Any news biopa 11/14/17 05:55:02 PM
#3125   What do you mean by "they got it H2R 11/13/17 11:02:29 PM
#3124   Its time to accumulate people, they got it harry crumb 11/13/17 10:36:47 PM
#3123   I agree with you. Despite the negative Stockdoggy 11/11/17 07:28:33 AM
#3122   Looking for some feedback. In my estimation KERX biopa 11/10/17 10:48:15 PM
#3121   I bought some ARTH, but not DVAX :( H2R 11/10/17 12:50:24 AM
#3120   Keep adding and if it goes down average hump4 11/09/17 07:51:04 PM
#3119   H2R did you buy DVAX? Their Heplisav-B vaccine lakingsphan0427 11/09/17 05:17:56 PM
#3118   SETH =going to take KERX private at around smile86 11/09/17 03:54:29 PM
#3117   I am sick to my stomach how KERX lakingsphan0427 11/09/17 11:44:41 AM
#3116   SA Entry on KERX: H2R 11/09/17 10:09:49 AM
#3115   Thanks for your comments. shadolane 11/08/17 11:51:47 AM
#3114   loaded 9 new lots 4.70’s-4.80 an all green harry crumb 11/08/17 11:39:32 AM
#3113   Analysts estimates are all based on pre-FDA approval, Vector93 11/08/17 10:49:26 AM
#3112   Right now KERX is a fking garbage.. lakingsphan0427 11/08/17 09:58:09 AM
#3111   But right now some analysts have KERX as shadolane 11/08/17 08:18:21 AM
#3110   agree, $$$$$ harry crumb 11/07/17 10:10:43 PM
#3109   great post an exactly! added 21.5k shares today harry crumb 11/07/17 10:09:05 PM
#3108   The Commercial Side After Approval H2R 11/07/17 10:08:12 PM
#3107   Exactly! fsulevine 11/07/17 09:52:09 PM
#3106   What a nutty day! H2R 11/07/17 05:41:27 PM
#3105   I’m going to take this as an opportunity Vector93 11/07/17 04:05:53 PM
#3104   I am definitely looking for a bounce and fsulevine 11/07/17 02:34:20 PM
#3103   Agreed, which is why I am pretty surprised fsulevine 11/07/17 02:32:51 PM
#3102   Surely! Cuppy 11/07/17 12:55:21 PM
#3101   Apparently the approval was already factored in. shadolane 11/07/17 12:32:52 PM
#3100   Yeah, I remember the good old days when Stockdoggy 11/07/17 11:14:58 AM
#3099   why would anybody think that something has to mrguitar33 11/07/17 10:57:08 AM
#3098   Rebounding some here... added a few more to Gateway_Stocks 11/07/17 10:00:46 AM
#3097   Bought another (small, not much cash laying around) H2R 11/07/17 09:59:40 AM
#3096   Atm KERX is junk.. lakingsphan0427 11/07/17 09:56:18 AM
#3095   Maybe this is what's confusing the market: H2R 11/07/17 09:55:29 AM
#3094   The next couple of earnings will dictate. The hump4 11/07/17 09:42:35 AM
#3093   Just don't understand this reaction... Oh well we Gateway_Stocks 11/07/17 09:28:45 AM
#3092   All I can say is WTF! SMH lakingsphan0427 11/07/17 09:21:01 AM
#3091   Their initial target population of patients is only Vector93 11/07/17 09:16:26 AM
#3090   Shorts are trying to get stock out of biopa 11/07/17 08:36:12 AM
#3089   What the approval means: H2R 11/07/17 08:36:01 AM
#3088   Or no good news will go unpunished. shadolane 11/07/17 08:21:58 AM
#3087   You mean sell on the rumour and sell hump4 11/07/17 08:05:49 AM
#3086   Revs were less than expected and guidance was Vector93 11/07/17 07:55:12 AM
PostSubject